Suzhou Highfine Biotech Management
Management criteria checks 4/4
Suzhou Highfine Biotech's CEO is Yong Zhu, appointed in Jan 2016, has a tenure of 9.83 years. directly owns 47.86% of the company’s shares, worth CN¥2.70B. The average tenure of the management team and the board of directors is 9.8 years and 6.7 years respectively.
Key information
Yong Zhu
Chief executive officer
CN¥634.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.8yrs |
| CEO ownership | 47.9% |
| Management average tenure | 9.8yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Subdued Growth No Barrier To Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Price
Dec 24
With A 26% Price Drop For Suzhou Highfine Biotech Co., Ltd. (SZSE:301393) You'll Still Get What You Pay For
Apr 16Why Suzhou Highfine Biotech's (SZSE:301393) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 15CEO
Yong Zhu (54 yo)
Mr. Yong Zhu is Chairman & GM of Suzhou Highfine Biotech Co. Ltd. from January 5, 2016.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 9.8yrs | CN¥634.20k | 47.86% CN¥ 2.7b | |
| Finance Manager | 21.8yrs | CN¥263.20k | no data | |
| Director & Deputy GM | 9.8yrs | CN¥565.50k | 4.89% CN¥ 276.3m | |
| Director & Deputy GM | 9.8yrs | CN¥521.10k | 1.86% CN¥ 105.3m | |
| Director & Deputy GM | 9.8yrs | CN¥521.50k | 1.86% CN¥ 105.3m | |
| R&D Director and Director | 4.4yrs | CN¥661.80k | no data | |
| Deputy GM & Secretary of the Board | 5.7yrs | CN¥512.60k | 2.03% CN¥ 114.8m | |
| Head of the Sales Department & Supervisor | 13.2yrs | no data | no data |
Experienced Management: 301393's management team is seasoned and experienced (9.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 9.8yrs | CN¥634.20k | 47.86% CN¥ 2.7b | |
| Director & Deputy GM | 9.8yrs | CN¥565.50k | 4.89% CN¥ 276.3m | |
| Director & Deputy GM | 9.8yrs | CN¥521.10k | 1.86% CN¥ 105.3m | |
| Director & Deputy GM | 9.8yrs | CN¥521.50k | 1.86% CN¥ 105.3m | |
| R&D Director and Director | 4.4yrs | CN¥661.80k | no data | |
| Head of the Sales Department & Supervisor | 6.7yrs | no data | no data | |
| Director | 6.7yrs | CN¥477.00k | no data | |
| Chairman of the Supervisory Board | 9.8yrs | no data | no data | |
| Employee Representative Supervisor | 6.8yrs | no data | no data | |
| Independent Director | 4.4yrs | CN¥72.00k | no data | |
| Independent Director | 4.4yrs | CN¥72.00k | no data | |
| Independent Director | 2.3yrs | CN¥72.00k | no data |
Experienced Board: 301393's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/09 21:23 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suzhou Highfine Biotech Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |